HCPLive

08/13/2026

This week, HCPLive teamed up with fellow MJH Life Sciences brand AJMC for a studio session with key opinion leaders on major depressive disorder (MDD). Our HCPLive team was on hand to ask the clinical questions our audience wants answered. Here's what's coming throughout the week:
🎥 Ken Cohen, MD (Optum Health)
Managing common antidepressant side effects without discontinuing treatment, plus how long a "failed" antidepressant trial should actually run before switching course.
🎥 Samuel Wilkinson, MD (Yale School of Medicine)
Why access to esketamine clinics remains so uneven across the US.
🎥 Michael Thase, MD (University of Pennsylvania Perelman School of Medicine)
A look at inhaled and novel rapid-acting antidepressants in the pipeline, plus guidance on neuromodulation options, including TMS, ECT, and VNS, and who's actually a candidate for each.
Check out a clip from Cohen here: https://hubs.li/Q04sQtFx0

08/12/2026

Yesterday, Novo Nordisk announced the commercial availability of insulin icodec (Awiqli) in the US. In a quick update from Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the new once-weekly dosing structure and what clinicians need to know.

Watch now: https://hubs.ly/Q04sH-rP0

08/12/2026

What does CKD management look like in 2026?

Matthew Breeggemann, MD, assistant clinical professor in the Division of Nephrology and medical director of the Kidney Stone Prevention Center at UCSF, shares his perspective on:

Why urine protein trends matter as much as eGFR
The 17 year gap between new therapies and routine clinical use
How AKI episodes raise long term risk of CKD progression
The role of genetic testing and risk stratification tools

Read the full conversation: https://hubs.ly/Q04sHHY80

08/12/2026

Sonelokimab hit its primary ACR50 endpoint and all key secondary endpoints in biologic-naive patients with psoriatic arthritis in the phase 3 IZAR-1 trial. Read more:

Sonelokimab hit its primary ACR50 endpoint and all key secondary endpoints in biologic-naive patients with psoriatic arthritis in the phase 3 IZAR-1 trial.

08/12/2026

Nonsteroidal treatment options for pediatric atopic dermatitis are expanding rapidly, and the systemic pipeline is heating up too. Eichenfield, MD, of and Children's Hospital, reviews recent approvals down to age 2, early data in infants as young as 3 months, and emerging systemic therapies that may soon offer alternatives to dupilumab in younger patients. Full breakdown here: https://hubs.ly/Q04sHFrN0

08/12/2026

A study found antibiotics before f***l microbiota transplantation raised the response rate to 60% from 30%. Watch our interview with Rima Rachid, MD, from Boston Children's Hospital, here:

Rima Rachid, MD, discussed why antibiotic pretreatment before f***l microbiota transplantation may improve peanut allergy response rates.

08/11/2026

In the latest episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss updates on ketone monitoring, insulin pumps, and more from ADCES 2026.

Watch now: https://hubs.li/Q04svqSF0

08/11/2026

New research links "forever chemicals" (PFAS) detected in cord blood to elevated gut inflammation markers in children — with the same PFAS metabolites tied to maternal IBD also showing up as top drivers of the effect in kids.

In this interview, Elizabeth A. Spencer, MD, pediatric gastroenterologist at Mount Sinai, breaks down what the new data — drawn from 3 birth cohorts — actually show, why PFAS mixtures (not single compounds) matter, and why this is an association, not a proven cause of IBD.

🎥 Full interview + article on https://hubs.li/Q04svqvk0

08/11/2026

Sarah Tomashefski, MSN, discusses where AATD diagnoses go missed and why APPs are positioned to close the gap. Learn more:

Tomashefski discusses where AATD diagnoses go missed and why APPs are positioned to close the gap.

08/11/2026

The Academy of Dermatology recently released its first pediatric-specific atopic dermatitis guidelines, addressing prevention strategies and associated comorbidities for the first time. Eichenfield, MD, of childrens hospital and , breaks down the evidence behind moisturizer use, why some commonly recommended prevention strategies don't hold up, and which comorbidities clinicians should be monitoring in pediatric patients. View his discussion: https://hubs.li/Q04svqKk0